View in EDS HTML Full Text PDF Full Text

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.

Saved in:
Bibliographic Details
Title: Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.
Authors: Hammitt LL; International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Quinn D; P3 Research, Wellington Clinical Trial Research Unit, Wellington, New Zealand., Janczewska E; The School of Health Sciences in Bytom, Medical University of Silesia, Bytom, Poland., Pasquel FJ; Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA., Tytus R; Family Medicine, McMaster University, Ontario, Canada., Reddy KR; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Abarca K; Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile., Khaertynova IM; Department of Infectious Diseases, Kazan State Medical Academy, Kazan, Russia., Dagan R; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences of the Ben-Gurion University of the Negev, Beer-Sheva, Israel., Dawson R; Merck & Co., Inc., Rahway, NJ, USA., McCauley J; Merck & Co., Inc., Rahway, NJ, USA., Shekar T; Merck & Co., Inc., Rahway, NJ, USA., Fu W; Merck & Co., Inc., Rahway, NJ, USA., Pedley A; Merck & Co., Inc., Rahway, NJ, USA., Sterling T; Merck & Co., Inc., Rahway, NJ, USA., Tamms G; Merck & Co., Inc., Rahway, NJ, USA., Musey L; Merck & Co., Inc., Rahway, NJ, USA., Buchwald UK; Merck & Co., Inc., Rahway, NJ, USA.
Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2177066. Date of Electronic Publication: 2023 Mar 02.
Publication Type: Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36864601
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hammitt+LL%22">Hammitt LL</searchLink>; International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Quinn+D%22">Quinn D</searchLink>; P3 Research, Wellington Clinical Trial Research Unit, Wellington, New Zealand.<br /><searchLink fieldCode="AU" term="%22Janczewska+E%22">Janczewska E</searchLink>; The School of Health Sciences in Bytom, Medical University of Silesia, Bytom, Poland.<br /><searchLink fieldCode="AU" term="%22Pasquel+FJ%22">Pasquel FJ</searchLink>; Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Tytus+R%22">Tytus R</searchLink>; Family Medicine, McMaster University, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Reddy+KR%22">Reddy KR</searchLink>; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Abarca+K%22">Abarca K</searchLink>; Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.<br /><searchLink fieldCode="AU" term="%22Khaertynova+IM%22">Khaertynova IM</searchLink>; Department of Infectious Diseases, Kazan State Medical Academy, Kazan, Russia.<br /><searchLink fieldCode="AU" term="%22Dagan+R%22">Dagan R</searchLink>; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences of the Ben-Gurion University of the Negev, Beer-Sheva, Israel.<br /><searchLink fieldCode="AU" term="%22Dawson+R%22">Dawson R</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22McCauley+J%22">McCauley J</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Shekar+T%22">Shekar T</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Fu+W%22">Fu W</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Pedley+A%22">Pedley A</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Sterling+T%22">Sterling T</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Tamms+G%22">Tamms G</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Musey+L%22">Musey L</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Buchwald+UK%22">Buchwald UK</searchLink>; Merck & Co., Inc., Rahway, NJ, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101572652%22">Human vaccines & immunotherapeutics</searchLink> [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2177066. <i>Date of Electronic Publication: </i>2023 Mar 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101572652 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2164-554X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221645515%22">21645515 </searchLink><i>NLM ISO Abbreviation: </i>Hum Vaccin Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36864601
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/21645515.2023.2177066
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2177066
    Titles:
      – TitleFull: Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hammitt LL
      – PersonEntity:
          Name:
            NameFull: Quinn D
      – PersonEntity:
          Name:
            NameFull: Janczewska E
      – PersonEntity:
          Name:
            NameFull: Pasquel FJ
      – PersonEntity:
          Name:
            NameFull: Tytus R
      – PersonEntity:
          Name:
            NameFull: Reddy KR
      – PersonEntity:
          Name:
            NameFull: Abarca K
      – PersonEntity:
          Name:
            NameFull: Khaertynova IM
      – PersonEntity:
          Name:
            NameFull: Dagan R
      – PersonEntity:
          Name:
            NameFull: Dawson R
      – PersonEntity:
          Name:
            NameFull: McCauley J
      – PersonEntity:
          Name:
            NameFull: Shekar T
      – PersonEntity:
          Name:
            NameFull: Fu W
      – PersonEntity:
          Name:
            NameFull: Pedley A
      – PersonEntity:
          Name:
            NameFull: Sterling T
      – PersonEntity:
          Name:
            NameFull: Tamms G
      – PersonEntity:
          Name:
            NameFull: Musey L
      – PersonEntity:
          Name:
            NameFull: Buchwald UK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 31
              M: 12
              Text: 2023 Dec 31
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2164-554X
          Numbering:
            – Type: volume
              Value: 19
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Human vaccines & immunotherapeutics
              Type: main
ResultId 1